Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Beximco Pharmaceuticals Ltd.

Latest From Beximco Pharmaceuticals Ltd.

The Quality Lowdown: More Concerns Raised About API Plants, Data Integrity And Sterility Assurance

Recent enforcement activities shed light on compliance challenges at ALI, UCB, Novo, Samsung, Nectar, Panacea and Beximco.

Quality Compliance

Beximco Profit Tumble Continues Amid Hostile Macro Climate

Beximco faced another quarter of declining profits despite growing revenue, as external headwinds including increased production costs took their toll on the firm.

Sales & Earnings Business Strategies

Expected Drop In COVID-19 Vaccine Sales Hits Beximco’s Bottom Line

The absence of any income from distributing AstraZeneca’s COVID-19 vaccine led to Beximco’s pre-tax profit dropping by 13% in the first six months of its financial year ending in June 2023. However, profits after tax actually rose slightly when discounting last year’s COVID-19 vaccine impact.

Sales & Earnings Business Strategies

International Trade Groups Call For Regulators To Protect Off-Patent Industry From Inflation

Rising inflation has exacerbated pressures in the off-patent drug sector, prompting Medicines for Europe and the US Association for Accessible Medicines to call for regulatory intervention to ensure the long-term sustainability of the space.

Business Strategies Market Intelligence
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs